Clinical trial · Interventional
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT
NCT05227534CI-TRIAL-00059518PREVENTrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Circulating Cell-free DNA | — | UNRESOLVED | — |
| Early Detection of Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OverC multi-cancer detection blood test | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants 40 years of age or older with cancer risk
- description
- The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.
- interventionNames
- Device: OverC multi-cancer detection blood test
Primary outcomes (2)
- measure
- The cancer clinical stages of cancer patients diagnosed via the multi-cancer detection blood test
- timeFrame
- Up to 5 years
- measure
- Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the multi-cancer detection test alone or with standard-of-care screening as evaluated after 1-year follow-up
- timeFrame
- Up to 1 year
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Participants must be able to provide a written informed consent form * Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form * Participants must be able to provide blood samples for study tests * Participants must be between 40 and 75 years old Exclusion Criteria: * Individuals who have an acute infection or inflammation within 14 days prior to recruitment * Individuals with cancer-associated clinical symptoms or suspected of cancer * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant * Recipient of blood transfusion within 7 days prior to recruitment * Individuals who have pure ground-glass opacity * Unable to provide blood samples for the multi-cancer early detection blood test * Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests * Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment * Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment * Individuals with hemorrhagic diseases * Individuals with autoimmune diseases * Individuals who are pregnant or lactating * Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
References
Publications (0)
Data not yet available
No reference posted for this study.